Skip to main content
. 2023 Jan 13;95(4):2329–2338. doi: 10.1021/acs.analchem.2c04220

Figure 3.

Figure 3

Application of MALDI-IHC to two FFPE breast cancer tissue samples to determine the HER2 status of the patients. Patient 1 (left) shows a low abundance of the HER2 mass reporter, while patient 2 (right) shows a high abundance of the HER2 mass reporter and therefore showed to be HER2+. The HER2 status (negative for patient 1, positive for patient 2) found with MALDI-IHC is consistent with the breast cancer pathology annotations provided with the samples.